Our sister site, Drug Delivery Business News, reports today that the company announced Medicare access for MiniMed 780G paired with the Instinct sensor made by Abbott, FDA clearance for the pairing for insulin-requiring type 2 diabetes and FDA clearance for the system’s use with ultra rapid-acting insulins.
Medtronic and Abbott entered a collaboration in August 2024 to pair insulin delivery and continuous glucose monitoring (CGM) technologies. Medtronic (soon to be a standalone company called MiniMed) launched the MiniMed 780G with the Instinct sensor made by Abbott late last year. The company further advanced the integrated offering with FDA 510(k) clearance for its MiniMed Go app for multiple daily injections (MDI) last month.
MiniMed 780G, the company’s latest-generation AID system, offers meal detection technology and provides automatic adjustments and corrections to sugar levels every five minutes. This occurs for both basal (background) and bolus (mealtime) insulin needs. The algorithm auto-corrects glucose levels to provide support for missed boluses or underestimated carbohydrates.
Get the full story at our sister site, Drug Delivery Business News.
